What is Step Pharma?
Step Pharma is a biotechnology company specializing in the development of novel therapeutics, stemming from research conducted at the Imagine Institute. Founded in 2014, it is a joint venture involving Imagine Institute, Sygil Group Ltd, and Kurma Partners. The company's focus is on addressing genetic immunodeficiencies, leveraging advanced research to create innovative healthcare solutions. Its strategic positioning within the European biotechnology landscape is bolstered by strong academic ties and robust financial backing.
How much funding has Step Pharma raised?
Step Pharma has raised a total of $102.5M across 3 funding rounds:
Series A
$17M
Series B
$41.4M
Series C
$44M
Series A (2017): $17M with participation from Inserm Transfert Initiative, Idinvest Partners, Sygnature Discovery, Kurma Partners, Pontifax, Imagine Institute, and Bpifrance
Series B (2021): $41.4M led by Sunstone Capital, Pontifax, KURMA PARTNERS SA, Bpifrance, and Hadean Ventures
Series C (2025): $44M supported by Kurma Partners, V-Bio Ventures, and Bpifrance
Key Investors in Step Pharma
Kurma Partners
Kurma Partners is a prominent player in funding healthcare and biotechnology ventures across Europe, specializing in investing at various maturity stages from inception to capital expansion. They focus on severe diseases with high unmet medical needs, transforming scientific discoveries into advanced medical solutions.
Pontifax
Pontifax Venture Capital specializes in groundbreaking innovations in life sciences, focusing on transformative healthcare technologies across all development stages. They actively scout disruptive ideas and build exceptional companies, providing strategic direction and expertise.
Bpifrance
Bpifrance finances companies at each stage of their development with credit, guarantees, and equity, supporting innovation projects and international expansion. They also provide consulting and networking services for entrepreneurs.
What's next for Step Pharma?
With the recent influx of major strategic investment, Step Pharma is poised for accelerated growth. The company is expected to channel these resources into advancing its pipeline of gene therapies and expanding its research and development capabilities. This capital infusion will likely support clinical trials, further scientific validation, and potential strategic partnerships, aiming to bring groundbreaking treatments for genetic diseases to patients. The company's trajectory suggests a focus on scaling operations and solidifying its position as a leader in genetic medicine.
See full Step Pharma company page
